다발성골수종 시장 규모, 점유율, 성장 분석, 약제 클래스별, 치료법별, 유통 채널별, 지역별 - 산업 예측(2024-2031년)

Global Multiple Myeloma Market size was valued at USD 21.98 billion in 2022 and is poised to grow from USD 25.30 billion in 2023 to USD 77.93 billion by 2031, growing at a CAGR of 15.1% in the forecast period (2024-2031).

The multiple myeloma market is experiencing significant momentum driven by increasing awareness and rising incidence of this rare blood cancer, primarily affecting plasma cells. As new therapeutics continue to emerge, the competitive landscape is evolving, with a marked uptick in treatment expertise among leading market participants. Reports, such as the Globocan 2020 data, highlight a staggering 19,292,789 new cancer diagnoses worldwide, alongside nearly 10 million cancer-related fatalities. The International Agency for Research on Cancer (IARC) projects that these numbers will escalate to 27.5 million new cases and 16.3 million deaths by 2031, with men facing a 1.5-fold higher risk than women. Key risk factors include lifestyle choices like smoking, alcohol use, and higher obesity rates among men, while the disease predominantly affects older adults, particularly those aged 55 to 65. Contributing to market growth is the increasing incidence of hematological cancers and a growing demand for healthcare infrastructure, research, and treatment options. However, the proliferation of the global multiple myeloma market is somewhat curtailed by low treatment rates in developing nations. As it stands, the US multiple myeloma market is anticipated to maintain a sustainable compound annual growth rate (CAGR) in the forthcoming years, as the healthcare sector intensifies its focus on combating this challenging disease.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Myeloma Market Segmental Analysis

Global Multiple Myeloma Market is segmented on the drug class, therapy, distribution channel, and region. By drug class, market is segmented into Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids. By therapy, market is segmented into immunotherapy, chemotherapy, radiation therapy, and stem cell transplant. By distribution channel, market is segmented into hospital, retail, and online pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Multiple Myeloma Market

The global multiple myeloma market is significantly driven by the increasing adoption of monoclonal antibodies, which are heralded for their high safety profile and targeted action against myeloma cells. Advances in nanomedicine and microRNA therapies, alongside the ongoing development of effective and safe treatments, are further propelling market growth. The integration of monoclonal antibodies, like Darzalex and Empliciti, with existing therapies enhances treatment efficacy, attracting clinician preference. Additionally, the rising incidence of hematological cancers, particularly multiple myeloma linked to specific genetic mutations, coupled with an aging population and rising healthcare costs, are amplifying the demand for innovative treatment solutions within this market.

Restraints in the Global Multiple Myeloma Market

The global multiple myeloma market is significantly restrained by low treatment rates in emerging nations, primarily driven by the high cost of treatments, which limits patient access. Furthermore, the scarcity of skilled healthcare professionals and inadequate healthcare infrastructure in these regions compound the issue, hindering effective diagnosis and treatment. The COVID-19 pandemic has exacerbated this situation, resulting in a notable decline in clinical visits and heightened reluctance among patients to seek medical care. Additionally, a pervasive lack of public awareness regarding multiple myeloma remains a critical barrier, ultimately impeding the market's growth potential throughout the forecast period.

Market Trends of the Global Multiple Myeloma Market

The global multiple myeloma market is experiencing a significant upward trend driven by increased research and development activities. This surge is fostering the introduction of novel therapies, evidenced by a rise in drug approvals and market entries, particularly in monoclonal antibodies like Darzalex and Empliciti. These advancements not only offer innovative treatment options, extending relapse intervals for patients, but also complement traditional therapies such as Revlimid and Velcade. Additionally, the emergence of second-generation proteasome inhibitors like Ninlaro and Kyprolis further diversifies treatment strategies, enhancing patient outcomes and solidifying the market's growth trajectory in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Of the Market
• Value Chain Analysis
• Raw Material Analysis
• Pricing Analysis
• Consumer Behaviour Analysis
• PESTEL Analysis

Multiple Myeloma Market, By Drug Class

• Market Overview
• Proteasome Inhibitors
• Immunomodulatory Drugs
• Monoclonal Antibodies
• Steroids

Multiple Myeloma Market, By Therapy

• Market Overview
• Immunotherapy
• Chemotherapy
• Radiation Therapy
• Stem Cell Transplant

Multiple Myeloma Market, By Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Multiple Myeloma Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen Pharmaceuticals) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (Bristol-Myers Squibb Company) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (F. Hoffmann-La Roche Ltd) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONO Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Oncology (Millennium Pharmaceuticals) (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oncopeptides AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments